Literature DB >> 1738440

Prophylactic hypervolemia without calcium channel blockers in early aneurysm surgery.

M D Medlock1, S C Dulebohn, P W Elwood.   

Abstract

Delayed ischemic neurological deficit (DIND) remains a major unsolved problem in the management of aneurysmal subarachnoid hemorrhage (SAH). For many years, the complications reported with acute aneurysm surgery caused surgeons to operate late after SAH. In a 42-month-period, we managed 146 patients with aneurysm and/or SAH. Forty-seven patients were characterized by the following: Hunt and Hess Grades I through III after an aneurysmal SAH; 2) clipping of their aneurysm within 72 hours of their SAH; and (3) prophylactic hypervolemia with a pulmonary artery catheter to optimize their fluid management. Forty of 47 (85%) had an excellent or good outcome, and 3 of 47 (6%) died. All of those who died had DIND. Nine of 47 (19%) patients developed DIND. There were 20 complications, primarily pulmonary edema, in 16 patients and one death related to prophylactic hypervolemia. It is not clear from our experience, when compared with results from other series, that hypervolemia provides any additional benefit to the patient as measured by a reduction in the risk of DIND or improved outcome. Despite aggressive volume expansion to the point of cardiovascular compromise, as evidenced by our high rate of pulmonary edema, we had no appreciable decrease in neurological morbidity and mortality when compared with results from recent reports.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1738440     DOI: 10.1227/00006123-199201000-00003

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  10 in total

1.  Reduction of pulmonary edema after SAH with a pulmonary artery catheter-guided hemodynamic management protocol.

Authors:  Dong H Kim; Charles L Haney; Grace Van Ginhoven
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 2.  Cardiovascular and pulmonary complications of aneurysmal subarachnoid hemorrhage.

Authors:  Nicolas Bruder; Alejandro Rabinstein
Journal:  Neurocrit Care       Date:  2011-09       Impact factor: 3.210

Review 3.  Routine management of volume status after aneurysmal subarachnoid hemorrhage.

Authors:  Stefan Wolf
Journal:  Neurocrit Care       Date:  2011-09       Impact factor: 3.210

Review 4.  Management of subarachnoid haemorrhage.

Authors:  T A Kopitnik; D S Samson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-09       Impact factor: 10.154

5.  Aneurysmal subarachnoid hemorrhage in patients with Hunt and Hess grade 4 or 5: treatment using the Guglielmi detachable coil system.

Authors:  Raymond U Weir; Mary L Marcellus; Huy M Do; Gary K Steinberg; Michael P Marks
Journal:  AJNR Am J Neuroradiol       Date:  2003-04       Impact factor: 3.825

6.  Aneurysmal bleeding. A plea for early surgery in good-risk patients.

Authors:  R T Thomeer; J C Taal; J H Voormolen; A R Wintzen
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

Review 7.  Advanced monitoring of systemic hemodynamics in critically ill patients with acute brain injury.

Authors:  Fabio Silvio Taccone; Giuseppe Citerio
Journal:  Neurocrit Care       Date:  2014-12       Impact factor: 3.210

8.  Effects of ischemic phrenic nerve root ganglion injury on respiratory disturbances in subarachnoid hemorrhage: an experimental study.

Authors:  Hızır Ulvi; Recep Demir; Recep Aygül; Dilcan Kotan; Muhammet Calik; Mehmet Dumlu Aydin
Journal:  Arch Med Sci       Date:  2013-11-29       Impact factor: 3.318

9.  Factors affecting outcome in poor grade subarachnoid haemorrhage: An institutional study.

Authors:  Sannepaneni Kranthi; Barada P Sahu; Purohit Aniruddh
Journal:  Asian J Neurosurg       Date:  2016 Oct-Dec

10.  Measuring serum matrix metalloproteinase-9 levels in peripheral blood after subarachnoid hemorrhage to predict cerebral vasospasm.

Authors:  Aykut Akpinar; Necati Ucler; Uzay Erdogan; Serhat S Baydin; Abuzer Gungor; Bekir Tugcu
Journal:  Springerplus       Date:  2016-07-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.